A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
NCT ID: NCT06603220
Last Updated: 2025-06-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
30 participants
INTERVENTIONAL
2024-08-14
2025-05-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)
NCT06873516
Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria
NCT06050928
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
NCT05936567
A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria
NCT04159701
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
NCT02477332
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EVO756
Oral EVO756
Oral EVO756, once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral EVO756
Oral EVO756, once daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Positive response following provocation using the TempTest or FricTest at Screening and Day 1.
Exclusion Criteria
* Concurrent use of certain medications, including antihistamines.
* Any clinically significant disease, or other skin disease or skin markings (e.g., extensive scarring, tattoos), that might confound the evaluation of safety or efficacy.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Evommune, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cahaba Dermatology & Skin Health Center, LLC
Birmingham, Alabama, United States
California Allergy and Asthma Medical Group
Los Angeles, California, United States
Integrative Skin Science and Research
Sacramento, California, United States
West Dermatology Research Center
San Diego, California, United States
Advanced Clinical Research Institute
Tampa, Florida, United States
Aeroallergy Research Laboratories of Savannah, Inc.
Savannah, Georgia, United States
Treasure Valley Medical Research
Boise, Idaho, United States
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, United States
Southern Indiana Clinical Trials
New Albany, Indiana, United States
Indiana Clinical Trials Center, P.C.
Plainfield, Indiana, United States
DelRicht Research
Baton Rouge, Louisiana, United States
Chesapeake Clinical Research, Inc
White Marsh, Maryland, United States
OptiSkin Medical
New York, New York, United States
Red River Research Partners
Fargo, North Dakota, United States
Bexley Dermatology Research
Bexley, Ohio, United States
Allergy, Asthma, and Clinical Research Center
Oklahoma City, Oklahoma, United States
Allergy and Clinical Immunology Associates
Pittsburgh, Pennsylvania, United States
Austin Institute for Clinical Research
Pflugerville, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EVO756-CIU001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.